Vitiligo: A manifestation of apoptosis?

American Journal of Clinical Dermatology

Volumn 3, Issue 5, 2002, Pages 301-308

  Huang, Carol L ^a   Nordlund, James J ^a   Boissy, Raymond ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; HYDROQUINONE; MELANIN; MONOBENZONE; PROTEIN BAX; PROTEIN BCL 2; PSORALEN;

APOPTOSIS; AUTOIMMUNITY; CELL DEATH; DEPIGMENTATION; DISEASE COURSE; DRUG TOLERABILITY; MELANOCYTE; MOLECULAR DYNAMICS; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUNBURN; ULTRAVIOLET RADIATION; VITILIGO;

EID: 0036310408     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203050-00001     Document Type: Review

References (116)

1. Mechanisms that cause abnormal skin color
2. Molecular basis of congenital hypopigmentary disorders in humans: A review
3. Piebaldism, Waardenburg syndrome and related genetic disorders of melanocyte development: Clinical aspects
4. Disorders of hypopigmentation and depigmentation
5. The differential diagnosis of vitiligo vulgaris
6. Melanocytes are not absent in lesional skin of long duration vitiligo
7. An electron microscope study of basal melanocytes and high-level clears cells (Langerhans cells) in vitiligo
8. Malignant melanoma and vitiligo-like leukoderma: An electron microscopic study
9. Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation
10. Expression of the c-kit receptor in hypomelanosis: A comparative study between piebaldism, naevus depigmentosus and vitiligo
11. Ultrastructural observations of dendritic cells in the repigmented area of vitiligo: Electron microscopic studies on dopa oxidase in melanocytes which are present between the epidermal basal cells in the repigmented area of vitiligo
12. The treatment of vitiligo with topical corticosteroids: Light and electronmicroscopic studies
13. Ultrastructural studies of vitiligo, Vogt-Koyanagi syndrome, and incontinentia pigmenti achromians
14. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo
15. Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse
16. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients
17. Histology of vitiliginous skin
18. Successful culture of adult human melanocytes obtained from normal and vitiligo donors
19. Role of hair follicles in the repigmentation of vitiligo
20. The melanocyte reservoir and its necessity
21. PUVA-induced repigmentation of vitiligo: A histochemical (split-DOPA) and ultrastructural study
22. PUVA-induced repigmentation of vitiligo: Scanning electron microscopy of hair follicles
23. Ultrastructural study of vitiligo
24. Melanocyte reservoir in vitiligo
25. Vitiligo vulgaris
26. Surgical treatment of pigmentary disorders
27. Surgical therapies for vitiligo
28. A critical review of apoptosis in historical perspective
29. Dendritic cell dynamics in progressive depigmentations: Distinctive cytokinetics of -dendritic cells revealed by electron microscopy
30. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo
31. Phagocytosis of melanin particles by human epidermal cells in vitro
32. Melanin pigmentation: An in vivo model for studies of melanosome kinetics within keratinocytes
33. Vitiligo: Where do we stand?
34. Chemical leukoderma: Fact or fancy
35. Depigmentation from 4-tertiary butyl catechol: An experimental study
36. On the etiology of vitiligo and gray hair
37. Occupational leukoderma
38. Occupational vitiligo due to paratertiary butylphenol and homologues
39. Occupational leukoderma from alkyl phenols
40. Occupational leucoderma following misuse of a disinfectant
41. Occupational vitiligo caused by para-tertiary-butylphenol, a trial of vitiligo, hepatosis and struma
42. Occupational vitiligo caused by paratertiary butylphenol
43. Occupational vitiligo induced by p-tert-butylphenol, a systemic disease?
44. Vitiligo from p-tert butylphenol; a contribution to the problem of the internal manifestations of this occupational disease
45. Detection of environmental depigmenting substances
46. Occupational vitiligo
47. Occupational depigmentation due to a hydroquinone-containing photographic developer
48. Vitiligo as an occupational disease
49. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol
50. Occupational leukoderma and contact dermatitis from paratertiary-butylphenol
51. Occupational vitiligo: Clinical and epidemiological aspects
52. Raccoon-like periorbital leukoderma from contact with swim goggles
53. Occupational vitiligo
54. Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber
55. Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol
56. Occupational leukoderma due to phenolic compounds in the ceramics industry?
57. Mechanism of depigmentation by hydroquinone
58. Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide: Consequences for DNA inactivation
59. Lipid peroxidation: Its mechanism, measurement, and significance
60. Cytotoxic effects of biphenyl and hydroxybiphenyls on isolated rat hepatocytes
61. Effects of commonly used mitogens on the cytotoxicity of 4-tertiary-butylphenol to human melanocytes
62. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity
63. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes
64. Kinetic study of the oxidation of 4-tert-butyl phenol by tyrosinase
65. Hydrogen peroxide-dependent 4 t-butylphenol hydroxylation by tyrosinase: A new catalytic activity
66. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert butylphenol and 4 tert butylcatechol
67. Alternative therapies for vitiligo
68. Pseudocatalase in the treatment of vitiligo
69. Evaluation of apoptotic cells induced by ultraviolet light B radiation in epidermal sheets stained by the TUNEL technique
70. Expression and modulation of apoptosis regulatory molecules in human melanocytes: Significance in vitiligo
71. Photochemotherapy of vitiligo: Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system
72. Oral trimethylpsoralen in the treatment of vitiligo
73. Psoralen photochemotherapy
74. Ultraviolet-B treatment of psoriasis in patients with concomitant vitiligo
75. Treatment of vitiligo with khellin and ultraviolet A
76. Phototherapy and photochemotherapy
77. Guidelines for the treatment of vitiligo
78. Treatment of vitiligo with 5-methoxypsoralen and selective ultraviolet phototherapy (SUP)
79. Autografting and PUVA: A combination therapy for vitiligo
80. Treatment of vitiligo with oral corticosteroids
81. Vitiligo treated with topical clobetasol propionate
82. Non-psoralen treatment of vitiligo; part I: Cosmetics, systemic coloring agents, and corticosteroids
83. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease
84. The scientific basis of skin cancer
85. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis
86. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels
87. Apoptosis and cytokine release induced by ionizing or ultraviolet B radiation in primary and immortalized human keratinocytes
88. Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells
89. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation
90. Antibodies to melanocytes in vitiligo
91. Expression of vitiligo antigen on a revertant line of hamster melanoma cells
92. The significance of vitiligo antibodies
93. Autoantibodies in vitiligo: Clinical significance
94. Antibodies to surface antigens of pigmented cells in animals with vitiligo
95. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo
96. Vitiligo and antibodies to melanocytes
97. Evidence for immunologic mechanisms in human vitiligo: Patients sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity
98. Serum antibodies in vitiligo patients
99. Identification of pigment cell antigens defined by vitiligo antibodies
100. Cytolytic antibodies to melanocytes in vitiligo
101. Vitiligo autoantibodies are effective against melanoma
102. Antigens and antibodies in malignant melanoma
103. The role of tyrosinase in autoimmune vitiligo
104. Characterization of vitiligo antigens
105. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells
106. Antimelanoma antibodies in swine with spontaneously regressing melanoma
107. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo
108. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
109. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: Evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)
110. Human immunodeficiency virus-associated vitiligo: Expression of autoimmunity with immunodeficiency?
111. Alopecia totalis and vitiligo in common variable immunodeficiency
112. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection
113. Polyautoimmune syndrome in common variable immunodeficiency
114. Vitiligo associated with the acquired immunodeficiency syndrome
115. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection